A recent study has brought to light the limitations of caspofungin, a widely used antifungal medication. The research suggests that the drug is effective only when its target enzyme is active.
This finding is particularly significant as serious fungal infections are on the rise, with many hospital-acquired cases becoming increasingly difficult to treat due to growing resistance.
Caspofungin is commonly employed in the treatment of Candida infections, but the study underscores the need for careful consideration of its application in clinical settings.